Teijin : Regenet Begins Full-scale Operations at Expanded Iwakuni Factory Providing Regenerative Medicine CDMO Services to Global Customers

Tokyo, March 11, 2026 --- Teijin Limited announced today that Teijin Regenet Co., Ltd., a Teijin Group company dedicated to contract development and manufacturing of regenerative medicine products, has commenced full-scale operations at its expanded Iwakuni Factory in Iwakuni City, Yamaguchi Prefecture. The second and final phase of this expansion, completed at the end of January 2026, includes additional cell culture rooms featuring a flexible "ballroom" layout, and a new Manufacturing Execution System (MES) that links all production steps and provides real-time visibility into inventory and operations. Together with the company's Kashiwanoha Facility in Chiba Prefecture, the Iwakuni Factory is a core hub for Teijin Regenet's operations as a contract development and manufacturing organization (CDMO).

"Our newly expanded Iwakuni Factory maximizes our ability to support global customers with end-to-end capabilities spanning development through commercialization of regenerative medicine products," said Yasushi Tanaka, President of Teijin Regenet. "This investment is a key part of our commitment to accelerating the industrialization of regenerative medicine, both in Japan and globally, by delivering flexible services based on cutting-edge research, cell culture, testing and manufacturing capabilities."

Established in 2023, Teijin Regenet specializes exclusively in CDMO services for regenerative medicine products. The company provides biotech venture firms and pharmaceutical companies with seamless, end-to-end support..

The Iwakuni Factory, which opened in 2024, has undergone two phases of expansion, enabling it to provide contract development as well as contract manufacturing services.. It is well positioned to handle contract development and manufacturing for a wide range of advanced therapies, including chimeric antigen receptor T-cell (CAR- T) therapies and induced pluripotent stem (iPS)cell-based products.

Now equipped with seven cell culture rooms, two quality-testing laboratories and one research laboratory, the 2,400 square meter Iwakuni Factory is capable of producing more than 1,000 Patient-specific Lots of CAR-T cell therapy products annually. All culture rooms comply with Good Gene, Cellular, and Tissue-based Products Manufacturing Practices (GCTP), Japan's regulatory framework for manufacturing and quality control of regenerative medicine products. Because the GCTP is an internationally aligned quality system, the Iwakuni Factory is also equipped to accept orders from global customers.

The facility holds a Regenerative Medicine Products Manufacturing License (General) and complies with Japan's Pharmaceuticals and Medical Devices Act.

The newly added cell culture rooms feature the "ballroom concept," a pillar-free, flexible layout where equipment is not fixed in place. By integrating fully closed, automated culture devices into the ballroom environment, Teijin Regenet can freely adjust a room's layout to accommodate product variations and change manufacturing processes. This approach enables simultaneous production of multiple products within a single room. It also optimizes employee movements to reduce workflow inefficiencies, resulting in labor savings and cost reductions.

In addition, Teijin Regenet has implemented a Manufacturing Execution System that connects production scheduling, resource allocation, monitoring and quality management data across both the Iwakuni Factory and the Kashiwanoha Facility. The MES enhances productivity, strengthens regional responsiveness and reinforces business continuity planning.

The Teijin Group, which also owns Japan Tissue Engineering, one of Japan's most successful regenerative medicine product developers,

aims to deliver new therapeutic options to patients awaiting innovative treatments. This effort is part of its long-term vision: "To be a company that supports the society of the future."

Iwakuni Factory

Teijin (TSE: 3401) is a technology-driven global group with two core businesses: high-performance materials and healthcare solutions. Established in 1918 as Japan's first rayon manufacturer, Teijin today comprises some 170 companies employing 20,000 people. Teijin is committed to its Purpose, "Pioneering solutions together for a healthy planet." Teijin works together with employees and external partners to achieve its Long-Term Vision, "To be a company that supports the society of the future." Teijin posted consolidated revenue of JPY 1,005.5 billion and total assets of JPY 1,061.3 billion in the fiscal year ending March 31, 2025.

Established in 2023, Teijin Regenet is a contract development and manufacturing organization (CDMO) for regenerative medical products. It operates the Kashiwanoha facility for contract development and cell processing, and the Iwakuni Factory for contract manufacturing.

Corporate Communication Department Teijin Limited

[email protected]